This article has been reviewed according to Science X's editorial process and policies . Editors have highlighted the following attributes while ensuring the content's credibility: Overview diagram representing the exchange of identifiers between the web trackers running on the browser context and native android apps controlling and generating persistent IDs using localhost sockets Credit: IMDEA Networks Institute An international research collaboration has recently uncovered a potential privacy abuse invo ...

STAT6 is a key transcription factor within the IL4/IL13 signaling pathways which act as drivers of inflammation in allergic conditions Nurix to receive a $15 million license extension fee from Sanofi under its 2019 collaboration agreement, bringing the total amount received by Nurix under this collaboration to date to $127 million Nurix is eligible for an additional $465 million in development, regulatory and commercial milestones associated with the STAT6 program as well as potential future royalties and ...

Singapore, Singapore--(Newsfile Corp. - May 30, 2025) - FingerMotion, Inc. (NASDAQ: FNGR) (the "Company" or "FingerMotion"), a mobile services, data, and technology company, is pleased to report its financial results for the fiscal year ended February 28, 2025. To review the full financial results, please view the Company's recent 10-K filing at www.sec.gov/edgar/search, which should be read in connection with this news release.FY 2025 Financial Summary (results expressed in US$ unless otherwise indicated) ...

Company Overview - Arvinas, Inc. is a clinical-stage biotechnology company focused on developing a new class of drugs based on targeted protein degradation [3] - The company is headquartered in New Haven, Connecticut and is listed on Nasdaq under the ticker ARVN [3] Drug Development - Arvinas is pioneering the PROTAC (PROteolysis Targeting Chimera) protein degrader platform, which aims to selectively and efficiently degrade disease-causing proteins [3] - The company is advancing multiple investigational drugs through clinical development, including: - Vepdegestrant, targeting the estrogen receptor for patients with locally advanced or metastatic ER+/HER2- breast cancer [3] - ARV-393, targeting BCL6 for relapsed/refractory non-Hodgkin Lymphoma [3] - ARV-102, targeting LRRK2 for neurodegenerative disorders [3] Upcoming Events - Management will participate in a fireside chat at the Jefferies Global Healthcare Conference on June 5 at 2:35 p.m. ET in New York City [1] - A live audio webcast of the presentation will be available on the company's website [2]

28 May 2025 | 3:15AM EDT Americas Media TV Viewership Tracker: L3 through week ending May 25th, 2025 and April Gauge We refresh our Nielsen TV ratings tracker for our US Media coverage (DIS, CMCSA, PARA, WBD, FOXA) that includes: 1) traditional ACM (average commercial minute) prime time and total day ratings across broadcast and cable; and 2) the Gauge for total TV viewing share by medium (reported monthly). This edition focuses on the April Gauge, C3 cable and broadcast ratings through week ending May 11th ...

Summary of Henry Schein (HSIC) 2025 Conference Call Company Overview - **Company**: Henry Schein, Inc. (HSIC) - **Date of Conference**: May 29, 2025 - **Key Speakers**: Ron South (CFO), Andrea Albertini (CEO, Global Distribution and Technology), Tom Popack (CEO, Henry Schein Products Groups) Key Industry Insights - **Market Recovery**: After a slow January attributed to weather, there was a notable recovery in February and March, with positive trends observed in both dental and medical sectors [2][5][7] - **Regulatory Uncertainty**: The introduction of tariffs and regulatory changes has created uncertainty in the market, affecting customer navigation and supplier dynamics [4] - **Dental and Medical Stability**: The dental market remains stable, while the medical sector saw an uptick due to a late flu season, leading to increased sales of diagnostic kits [5] Core Business Initiatives - **Specialty Products Sales**: The distribution sales force is now selling specialty products, particularly in the endodontic business, which has shown strong market share and momentum [9][10][13] - **Implant Market Growth**: The company is experiencing mid to high single-digit growth in the implant market in Europe, while the U.S. market remains relatively flat due to macroeconomic conditions [20][22] - **Global E-commerce Platform**: A new e-commerce platform was launched in the UK and Ireland, with plans for a broader rollout in the U.S. and Canada in 2026. This initiative aims to enhance customer experience and operational efficiency [25][31] Financial Performance and Projections - **Long-term Growth Goals**: The company aims for 8% to 11% EPS growth, contingent on achieving 6% to 8% top-line growth, which is currently challenged by lower market growth rates in core dental and medical sectors [34][35] - **Restructuring Savings**: A restructuring plan initiated last year is expected to yield annual savings of $75 million to $100 million, contributing positively to the cost base by the end of 2025 [37] - **Technology Segment Growth**: The technology segment is expected to return to high single-digit growth, driven by the transition from on-premise to SaaS models, despite current low single-digit growth rates [44][46] Market Challenges and Opportunities - **DSO Relationships**: The company emphasizes the importance of strategic partnerships with Dental Service Organizations (DSOs) to drive profitability rather than engaging in price competition [56][58] - **Medical Segment Growth**: The medical business is projected to achieve a CAGR of 4% to 7%, with home solutions contributing significantly to this growth [61][62] - **KKR Involvement**: KKR's investment is expected to enhance operational efficiency and revenue enhancement initiatives, although it is still in the early stages of collaboration [63][64] Additional Insights - **Equipment Orders**: There is optimism regarding equipment orders, although macroeconomic concerns may lead to delays in installations and revenue recognition [40][41] - **Customer Experience Focus**: The company is working on improving customer experience through loyalty programs and targeted promotions, particularly for online shoppers [30][28] This summary encapsulates the key points discussed during the Henry Schein conference call, highlighting the company's performance, strategic initiatives, and market outlook.

Summary of PolyPid (PYPD) Conference Call Company Overview - PolyPid is a clinical-stage biopharmaceutical company focused on drug delivery platforms, specifically the PLEX (polymer lipid encapsulation metrics) technology [2][4] - The company is based in Israel and has capabilities in R&D, regulatory, clinical, and manufacturing [4] PLEX Technology - PLEX allows for the prolonged release of various active pharmaceutical ingredients (APIs) over days to months, significantly longer than competitors who offer 72 to 96 hours [3] - The lead product, DIPLEX 100, is nearing the end of Phase 3 trials, with data expected by the end of the current quarter [3][16] DIPLEX 100 Product Details - DIPLEX 100 combines the PLEX platform with doxycycline to prevent surgical site infections (SSIs) post-abdominal surgeries [7][10] - The product is designed for a 30-day release, aligning with CDC guidelines for SSIs [11] - The total addressable market includes approximately 12 million procedures annually in the U.S. and 8 million in Europe [11][24] Clinical Trials and Results - The Phase 3 trial (SHIELD 2) involves 800 patients comparing DIPLEX 100 with standard IV antibiotics [16][18] - Previous trial (SHIELD 1) showed a 55% reduction in infection rates, 40% reduction in mortality, and 55% reduction in reintervention rates [22] - The trial is designed to meet both FDA and EMEA requirements, with plans for simultaneous filings in the U.S. and Europe [24] Commercial Strategy - The pricing strategy is approximately $600 per vial, with an average of 2.2 vials used per procedure [25] - The company is targeting hospitals directly, as they bear the costs of infections, which can be substantial [26][28] - PolyPid has partnered with Advanced Pharma for European commercialization, valued at over $110 million [30] Financial Position - The company ended the last quarter with $8 million, sufficient to fund operations through Q3 [34] - There are $27 million in warrants tied to trial success, with additional potential funding from commercial partners [35][47] Future Directions - Post-trial, resources will be allocated to other products like OncoPlex, which combines PLEX with chemotherapy for solid tumors [41][42] - The company is exploring additional applications for the PLEX platform in various local treatments [44] Key Takeaways - PolyPid is positioned to address a significant market need with its innovative DIPLEX 100 product, backed by promising clinical trial results and a solid commercialization strategy [11][22][30] - The financial structure appears robust, with multiple avenues for funding and a clear path to market entry following successful trial outcomes [35][47]

Salesforce Inc CRM reported better-than-expected first-quarter financial results after the market close on Wednesday.Salesforce reported first-quarter revenue of $9.83 billion, beating the consensus estimate of $9.75 billion. The company reported first-quarter adjusted earnings of $2.58 per share, beating analyst estimates of $2.55 per share, according to Benzinga Pro."We've built a deeply unified enterprise AI platform — with agents, data, apps and a metadata platform — that is unmatched in the industry. W ...

Financial Data and Key Metrics Changes - The company reported net sales of $400.4 million for the fourth fiscal quarter, representing a decline of 11.7% compared to the prior year [4][14] - Adjusted EBITDA for the quarter was $47.1 million, or 11.8% of net sales, down from 12.1% in the same period last year [8][16] - Adjusted net income was $24 million, or $1.61 per diluted share, compared to $28.2 million, or $1.78 per diluted share last year [16] - The gross profit margin decreased by 160 basis points to 17% of net sales from 18.6% in the prior year [15] - For the full fiscal year, net sales were $1.7 billion, a decrease of 7.5% year-over-year [18] Business Line Data and Key Metrics Changes - Remodel net sales, which include home centers and independent dealers, decreased by 10.4% in the fourth quarter [14] - New construction net sales decreased by 13.4% for the quarter compared to last year [14] - The home center business saw a low single-digit negative comp, while the pro business reported a positive comp for the quarter [5][6] Market Data and Key Metrics Changes - Existing home sales fell by 0.5% month-over-month to a seasonally adjusted rate of 4 million in April 2025, with a year-over-year decline of 2% [4] - The NAHB housing market index fell to 34 in May, marking the lowest level since November 2023 [7] - Single-family housing starts experienced negative comps from January to April [7] Company Strategy and Development Direction - The company focuses on three main strategic pillars: growth, digital transformation, and platform design [10] - Key accomplishments include product innovation, capacity investments, and channel expansion, with over 30% of made-to-order sales coming from products launched in the last three years [10][11] - The company is enhancing its manufacturing capabilities and transitioning independent distributor customers to a new brand [11][12] Management's Comments on Operating Environment and Future Outlook - The management expects demand trends to remain challenging, with net sales for fiscal year 2026 projected to range from low single-digit declines to low single-digit increases [9][20] - The outlook is influenced by macroeconomic factors, including interest rates, tariff changes, and consumer behavior [20] - Management believes that a decline in mortgage rates and increased consumer confidence could positively impact the housing market [9] Other Important Information - The company repurchased 1.17 million shares during fiscal year 2025, representing about 7.5% of outstanding shares [19] - Free cash flow totaled $65.7 million for the current fiscal year, down from $138.5 million in the prior year [18] - The company has a net leverage ratio of 1.56 times adjusted EBITDA at the end of the fourth quarter [19] Q&A Session Summary Question: Impact of tariffs on full year guidance - Management indicated that the outlook was significantly influenced by tariffs, estimating a cost impact of approximately $20 million [26][27] Question: Gross margin improvement - The improvement in gross margins was attributed to operational adjustments made in response to previous demand softness [28][30] Question: Revenue guidance assumptions - The revenue guidance assumes a recovery in both remodel and new construction markets in the second half of fiscal year 2026 [35][36] Question: Cost side considerations - Management acknowledged potential commodity inflation and labor costs as factors to consider for the full year guidance [43] Question: Savings from facility closure - The closure of a components facility is expected to yield annual savings of $5 million to $6 million [45] Question: Automation investments progress - Management described the company as being in the early stages of its automation investment journey, with significant spending planned for fiscal year 2026 [53][54]

Aurora Mobile (JG) Q1 2025 Earnings Call May 29, 2025 07:30 AM ET Company Participants René Vanguestaine - IRWeidong Luo - Co-Founder, Chairman and CEOShan-Nen Bong - CFO Conference Call Participants None - AnalystYuecong (Marco) Zhang - Senior Research Analyst Operator Ladies and gentlemen, thank you for standing by, and welcome to the Aurora Mobile First Quarter twenty twenty five Earnings Conference Call. At this time, all participants are in a listen only mode. After the speakers' presentation, there wi ...